Actively Recruiting
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
Led by Mansoura University · Updated on 2025-01-20
100
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.
CONDITIONS
Official Title
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older who are hospitalized for hypervolemic acute heart failure with evidence of congestion, including at least two of the following: peripheral edema, ascites, jugular venous pressure > 10 mmHg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound; or pulmonary capillary wedge pressure > 19 mmHg with physical exam signs of hypervolemia if pulmonary artery catheterization is available
- Randomized within 24 hours of hospitalization for acute heart failure
- Planned use of intravenous loop diuretic therapy during current hospitalization
- Estimated glomerular filtration rate (eGFR) of at least 30 ml/min/1.73m2 by the MDRD equation
You will not qualify if you...
- Unable to follow instructions
- Treated with any proximal tubular diuretics
- Systolic blood pressure less than 90 mm Hg
- Estimated glomerular filtration rate (GFR) less than 20 ml per 1.73 m2 of body surface area
- Diagnosed with type 1 diabetes mellitus
- Dyspnea mainly due to non-cardiac causes
- Cardiogenic shock
- Acute coronary syndrome within 30 days before randomization
- Planned or recent percutaneous or surgical coronary intervention within 30 days before randomization
- Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH > 7.30 and glucose > 15 mmol/L and HCO3 > 18 mmol/L)
- Pregnant or nursing (lactating) women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Noha Mansour
Al Mansurah, Egypt, 35516
Actively Recruiting
Research Team
H
Hossameldin Sharaf, BSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here